Understand the source comparison
The Unvarnished Truth About Cerebrolysin vs Aducanumab
Here's the honest answer: cerebrolysin vs aducanumab isn't a fair comparison because they target entirely different stages of neurodegeneration. Cerebrolysin supports a brain's attempt to repair itself through endogenous neurotrophic signaling. Aducanumab trie
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Here's the honest answer: cerebrolysin vs aducanumab isn't a fair comparison because they target entirely different stages of neurodegeneration. Cerebrolysin supports a brain's attempt to repair itself through endogenous neurotrophic signaling. Aducanumab tries to undo damage already done by clearing protein aggregates after they've formed. One prevents decline; the other attempts reversal. The research community's mistake is treating them as interchangeable 'neuroprotective agents' when the biological processes couldn't be more distinct. If your model doesn't have amyloid plaques, aducanumab is experimentally useless. If you're not measuring synaptic endpoints, cerebrolysin's effects go undetected. The cerebrolysin vs aducanumab debate only makes sense when both mechanisms are relevant to the research question. And in most models, only one applies.
- Aducanumab's FDA approval under the accelerated pathway was controversial precisely because Phase III trials showed amyloid clearance without consistent cognitive benefit. Meaning the antibody worked mechanistically but didn't translate to functional rescue. Cerebrolysin lacks FDA approval as a drug in most jurisdictions but has decades of clinical trial data in stroke and TBI showing synaptic preservation. Neither compound is a 'cure'. They're research tools for isolating specific pathways.